PH26542A - Use of X-phenyl-1,2,3,4-tetrahydro-1-naphthaleneamine derivatives in the treatment of psychosis inflammation and as immunosuppressants - Google Patents
Use of X-phenyl-1,2,3,4-tetrahydro-1-naphthaleneamine derivatives in the treatment of psychosis inflammation and as immunosuppressants Download PDFInfo
- Publication number
- PH26542A PH26542A PH40157A PH40157A PH26542A PH 26542 A PH26542 A PH 26542A PH 40157 A PH40157 A PH 40157A PH 40157 A PH40157 A PH 40157A PH 26542 A PH26542 A PH 26542A
- Authority
- PH
- Philippines
- Prior art keywords
- tetrahydro
- compound
- cis
- naphthalenamine
- dichlorophenyl
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title claims description 8
- 206010061218 Inflammation Diseases 0.000 title abstract description 5
- 230000004054 inflammatory process Effects 0.000 title abstract description 5
- 229960003444 immunosuppressant agent Drugs 0.000 title description 5
- 239000003018 immunosuppressive agent Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 230000000561 anti-psychotic effect Effects 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- LTKRQOGLVNJKBK-FVRDMJKUSA-N (4s)-4-(3,4-dichlorophenyl)-n,n-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CCC(C3=CC=CC=C32)N(C)C)=CC=C(Cl)C(Cl)=C1 LTKRQOGLVNJKBK-FVRDMJKUSA-N 0.000 claims 1
- IWNWWVPLTTUPBQ-UHFFFAOYSA-N 4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C12=CC=CC=C2C(N)CCC1C1=CC=CC=C1 IWNWWVPLTTUPBQ-UHFFFAOYSA-N 0.000 abstract description 3
- HTSNFXAICLXZMA-UHFFFAOYSA-N 3-(1-propyl-3-piperidinyl)phenol Chemical compound C1N(CCC)CCCC1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-UHFFFAOYSA-N 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108010085082 sigma receptors Proteins 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- SBRLSQHYWNDGMV-NSHDSACASA-N (4s)-4-(3,4-dichlorophenyl)-3,4-dihydro-2h-naphthalene-1,1-diamine Chemical compound C1([C@@H]2CCC(C3=CC=CC=C32)(N)N)=CC=C(Cl)C(Cl)=C1 SBRLSQHYWNDGMV-NSHDSACASA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010014557 Emotional poverty Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/320,014 US4981870A (en) | 1989-03-07 | 1989-03-07 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26542A true PH26542A (en) | 1992-08-19 |
Family
ID=23244506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH40157A PH26542A (en) | 1989-03-07 | 1990-03-07 | Use of X-phenyl-1,2,3,4-tetrahydro-1-naphthaleneamine derivatives in the treatment of psychosis inflammation and as immunosuppressants |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US4981870A (da) |
| EP (1) | EP0386997B1 (da) |
| JP (2) | JPH0714870B2 (da) |
| KR (1) | KR920005810B1 (da) |
| AT (1) | ATE150299T1 (da) |
| AU (1) | AU610036B2 (da) |
| CA (1) | CA2011428C (da) |
| DE (1) | DE69030212T2 (da) |
| DK (1) | DK0386997T3 (da) |
| HU (1) | HU221624B1 (da) |
| IE (1) | IE81047B1 (da) |
| IL (1) | IL93576A (da) |
| MY (1) | MY106272A (da) |
| NZ (1) | NZ232800A (da) |
| PH (1) | PH26542A (da) |
| PT (1) | PT93351B (da) |
| ZA (1) | ZA901743B (da) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
| WO1991009594A1 (en) * | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| ES2060547B1 (es) * | 1992-06-04 | 1995-06-16 | Ferrer Int | Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina". |
| CA2166100A1 (en) * | 1993-06-23 | 1995-01-05 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| ES2074946B1 (es) * | 1993-07-19 | 1996-06-16 | Ferrer Int | Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida. |
| US20040208926A1 (en) * | 1997-07-01 | 2004-10-21 | Pfizer Inc | Solubilized sertraline compositions |
| SK180499A3 (en) | 1997-07-01 | 2001-08-06 | Pfizer | Sertraline salts and sustained-release dosage forms of sertraline |
| US20030133974A1 (en) * | 1997-07-01 | 2003-07-17 | Curatolo William John | Encapsulated solution dosage forms of sertraline |
| JP2003518487A (ja) | 1999-12-23 | 2003-06-10 | ファイザー・プロダクツ・インク | ヒドロゲル駆動型積層薬物製剤 |
| ATE445838T1 (de) | 2001-07-25 | 2009-10-15 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
| US6988556B2 (en) * | 2002-02-19 | 2006-01-24 | Halliburton Energy Services, Inc. | Deep set safety valve |
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| JP4610336B2 (ja) * | 2002-09-16 | 2011-01-12 | セプラコール インク． | トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドによる中枢神経系障害の治療 |
| CA2498175A1 (en) * | 2002-09-16 | 2004-03-25 | Sepracor Inc. | Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| CZ2006427A3 (cs) * | 2003-12-29 | 2006-11-15 | Sepracor Inc. | Pyrrolové a pyrazolové inhibitory DAAO |
| EP2671508B1 (en) | 2005-04-28 | 2020-09-16 | Proteus Digital Health, Inc. | Pharma-informatics system |
| MX2008000250A (es) * | 2005-07-06 | 2008-03-19 | Sepracor Inc | Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y |
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| KR101381768B1 (ko) * | 2006-01-06 | 2014-04-07 | 선오비온 파마슈티컬스 인코포레이티드 | 테트랄론-기재 모노아민 재흡수 저해제 |
| CA2636324C (en) * | 2006-01-06 | 2012-03-20 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| ES2643602T3 (es) | 2006-03-31 | 2017-11-23 | Sunovion Pharmaceuticals Inc. | Aminas y quirales |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| RU2008152404A (ru) * | 2006-05-31 | 2010-07-10 | Сепракор Инк. (Us) | Лечение болевых расстройств транс 4-(3, 4-дихлорфенил)-1, 2, 3, 4-тетрагидро-1-нафталинамином и его формамидом |
| US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| CA2663377A1 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080082066A1 (en) * | 2006-10-02 | 2008-04-03 | Weyerhaeuser Co. | Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks |
| FR2909376A1 (fr) * | 2006-11-30 | 2008-06-06 | Cerep Sa | Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables |
| EP2074092A2 (en) * | 2007-01-18 | 2009-07-01 | Sepracor Inc. | Inhibitors of d-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| CN103936605B (zh) | 2007-05-31 | 2017-09-01 | 赛诺维信制药公司 | 苯基取代的环烷胺作为一元胺再摄取抑制剂 |
| WO2010017418A1 (en) * | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| JP2012526144A (ja) | 2009-05-06 | 2012-10-25 | ラボラトリー スキン ケア インコーポレイテッド | 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法 |
| US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
| EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
| AU2015259346A1 (en) * | 2014-05-13 | 2016-12-08 | Sunovion Pharmaceuticals Inc. | Dosage of dasotraline and method for treatment of ADHD |
| MX2016014780A (es) * | 2014-05-13 | 2017-07-25 | Sunovion Pharmaceuticals Inc | Metodos y composiciones de dasotralina para el tratamiento del adhd. |
| WO2016046669A2 (en) * | 2014-09-27 | 2016-03-31 | Mohan M Alapati | Compositions and methods for the treatment of depression and neurological diseases |
| BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
| FR3071726B1 (fr) * | 2017-09-29 | 2020-09-04 | Univ Paris Sud | Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1420472A (en) * | 1972-09-27 | 1976-01-07 | Pfizer | Aminophenyltetralin compounds |
| JPS59497B2 (ja) * | 1979-11-01 | 1984-01-07 | フアイザ−・インコ−ポレ−テツド | トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体 |
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4792448A (en) * | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
-
1989
- 1989-03-07 US US07/320,014 patent/US4981870A/en not_active Expired - Lifetime
-
1990
- 1990-02-28 IL IL9357690A patent/IL93576A/en not_active IP Right Cessation
- 1990-03-05 CA CA002011428A patent/CA2011428C/en not_active Expired - Fee Related
- 1990-03-05 MY MYPI90000347A patent/MY106272A/en unknown
- 1990-03-06 DK DK90302365.3T patent/DK0386997T3/da active
- 1990-03-06 NZ NZ232800A patent/NZ232800A/en unknown
- 1990-03-06 AT AT90302365T patent/ATE150299T1/de not_active IP Right Cessation
- 1990-03-06 AU AU50796/90A patent/AU610036B2/en not_active Ceased
- 1990-03-06 HU HU9001325A patent/HU221624B1/hu not_active IP Right Cessation
- 1990-03-06 DE DE69030212T patent/DE69030212T2/de not_active Expired - Fee Related
- 1990-03-06 PT PT93351A patent/PT93351B/pt not_active IP Right Cessation
- 1990-03-06 KR KR1019900002912A patent/KR920005810B1/ko not_active IP Right Cessation
- 1990-03-06 JP JP2054802A patent/JPH0714870B2/ja not_active Expired - Fee Related
- 1990-03-06 EP EP90302365A patent/EP0386997B1/en not_active Expired - Lifetime
- 1990-03-07 PH PH40157A patent/PH26542A/en unknown
- 1990-03-07 ZA ZA901743A patent/ZA901743B/xx unknown
- 1990-03-07 IE IE79890A patent/IE81047B1/en not_active IP Right Cessation
- 1990-12-05 US US07/622,308 patent/US5061728A/en not_active Expired - Lifetime
-
1994
- 1994-07-25 JP JP6172929A patent/JP3020808B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MY106272A (en) | 1995-04-29 |
| AU5079690A (en) | 1990-09-20 |
| PT93351A (pt) | 1990-11-07 |
| KR920005810B1 (ko) | 1992-07-20 |
| DE69030212D1 (de) | 1997-04-24 |
| JPH0714870B2 (ja) | 1995-02-22 |
| HUT59000A (en) | 1992-04-28 |
| ATE150299T1 (de) | 1997-04-15 |
| CA2011428A1 (en) | 1990-09-07 |
| EP0386997A2 (en) | 1990-09-12 |
| US4981870A (en) | 1991-01-01 |
| DE69030212T2 (de) | 1997-06-26 |
| IL93576A (en) | 1995-12-08 |
| IE900798L (en) | 1990-09-07 |
| KR900013949A (ko) | 1990-10-22 |
| EP0386997B1 (en) | 1997-03-19 |
| JPH02300121A (ja) | 1990-12-12 |
| ZA901743B (en) | 1991-10-30 |
| HU901325D0 (en) | 1990-05-28 |
| PT93351B (pt) | 1996-03-29 |
| HU221624B1 (hu) | 2002-12-28 |
| DK0386997T3 (da) | 1997-04-14 |
| AU610036B2 (en) | 1991-05-09 |
| IE81047B1 (en) | 1999-12-01 |
| US5061728A (en) | 1991-10-29 |
| NZ232800A (en) | 1997-07-27 |
| JPH07173056A (ja) | 1995-07-11 |
| JP3020808B2 (ja) | 2000-03-15 |
| CA2011428C (en) | 1994-11-08 |
| EP0386997A3 (en) | 1992-04-29 |
| IL93576A0 (en) | 1990-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4981870A (en) | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants | |
| DE69233462T2 (de) | Zusammensetzung die Tramadol und ein nichtsteroides entzündungshemmenden Mittel enthält | |
| AU670232B2 (en) | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | |
| JPH03500897A (ja) | 精神分裂病治療用組成物 | |
| NZ198953A (en) | (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine,its salts and pharmaceutical formulations | |
| JP2012508765A (ja) | ファルネシルトランスフェラーゼ阻害剤を使用するタンパク症の治療 | |
| DE69226447T2 (de) | NMDA Antagonisten | |
| CA1228818A (en) | Treatment of seizure disorders and pharmaceutical compositions useful therein | |
| AU608922B2 (en) | Method for the treatment of anxiety | |
| US20230133108A1 (en) | 2-bromo-lysergic acid diethylamide for substance abuse | |
| AU606531B2 (en) | Method of ameliorating epileptic seizures | |
| JPH05132430A (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| US20050070577A1 (en) | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist | |
| CA2168265C (en) | Antidepressant | |
| US4053637A (en) | Compounds of diphenylcyclopentylamine type and methods for their uses | |
| US20060189599A1 (en) | Treating alcohol and or substance abuse by antagonizing alpha 2 adrenergic receptors with weak dopamine blocking | |
| EP3928777A1 (en) | 4,5-dihydro-oxazol-2-ylamine derivatives for use in the prevention or treatment of alcohol use disorder | |
| US5037848A (en) | Aryl-cycloalkyl-alkanolamines for treatment of epilepsy | |
| US7432296B2 (en) | Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds | |
| KR20010108466A (ko) | 우울증 치료용 ｇａｂａ 유사체와 삼환계 화합물의 복합제제 | |
| DE3686538T2 (de) | Verwendung von dibenz(cd,f)indol-derivaten zur praevention vom alkoholmissbrauch. | |
| WO1993010788A1 (en) | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone | |
| Hricik | The pharmacological effects of d, 1-norephedrine and constituent enantiomers on tritiated norepinephrine uptake and release in isolated caudal artery tissue | |
| Wong et al. | DEVELOPMENT OF ANTIDEPRESSANT DRUGS | |
| AU4278199A (en) | Use of a nk-1 receptor antagonist for treating psychiatric disorders |